This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Protein patterns in melanoma tumors can predict how patients respond to immunotherapy and can be used to find promising biomarkers and drug targets, according to two new University of Pittsburgh studies.
The companion studies, published in Cancer Discovery and Clinical Cancer Research, developed a molecular atlas of melanoma and a method of classifying and predicting immunotherapy response based on protein patterns. Determining which patients are most likely to respond to immunotherapy before treatment begins may allow patients who are unlikely to benefit to avoid harmful side effects and prevent delays in starting better treatment options.
Immune checkpoint inhibitors, a type of cancer immunotherapy, have dramatically improved melanoma patient survival in the last 15 years. But a large percentage of patients don't respond to the treatment, and biomarkers that predict treatment response remain elusive. To better understand why some patients are resistant to the treatment, researchers looked to the proteome, the entire set of proteins expressed in a tissue or organism.
"In 2003, we decoded the human genome. , associate professor of medicine at Pitt and co-leader of the Cancer Immunology and Immunotherapy Program at UPMC Hillman Cancer Center.
Source link







